Scinai Immunotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 129.6%.

Top 19 shareholders own 15.22% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
7.44%	Daniel Stone	62,400	€233.9k	0%	no data
5.1%	Angels High Tech Investments Ltd	42,740	€160.2k	0%	no data
2.13%	Sabby Management, LLC	17,828	€66.8k	-29.6%	0.33%
0.29%	Amir Reichman	2,400	€9.0k	0%	no data
0.14%	Rhumbline Advisers Ltd Partnership	1,138	€4.3k	71.1%	no data
0.03%	Morgan Stanley, Investment Banking and Brokerage Investments	255	€956.0	-0.78%	no data
0.025%	UBS Asset Management AG	211	€791.0	0%	no data
0.017%	Geode Capital Management, LLC	140	€524.7	2.94%	no data
0.013%	George Lowell	105	€393.6	0%	no data
0.012%	Bank of America Corporation, Asset Management Arm	100	€374.7	0%	no data
0.0081%	Avner Rotman	68	€255.0	33.3%	no data
0.0063%	Adi Raviv	53	€198.7	43.2%	no data
0.005%	Amundi Asset Management SAS	42	€157.5	0%	no data
0.0039%	Morris Laster	33	€123.9	94.1%	no data
0.0039%	Yael Margolin	33	€123.9	94.1%	no data
0.0038%	Aspire Private Capital, LLC	32	€120.1	100%	no data
0.0025%	Jay Green	21	€78.6	0%	no data
0.0024%	Main Street Group, Ltd	20	€74.8	0%	no data
0.0006%	Global Retirement Partners, LLC	5	€18.9	0%	no data